The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.

Novartis sees itself engaging in only modest M&A activity to avoid over-paying for targets - and will rely on newly launched drugs and promising external targets to grow sales.

Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.